Abeona Stock Gains As It Concludes Type B Meeting With FDA For MPS IIIA Gene Therapy


Abeona Therapeutics Inc ABEO has completed a Type B meeting with the FDA regarding the pivotal trial for its ABO-102 gene therapy for Sanfilippo syndrome type A (MPS IIIA). 

  • ABO-102 is currently being evaluated in the single-arm Transpher A study in patients with MPS IIIA.
  • Based on the Type B meeting with the FDA, the ongoing Transpher A study will serve as the pivotal study for ABO-102 and could potentially support a marketing application submission depending on the data set. 
  • In addition, Abeona also aligned with the FDA to define the primary endpoint for the study. 
  • Abeona intends to work closely with the FDA through the regenerative medicine advanced therapy (RMAT) mechanism to assemble the most robust pivotal data package possible for the registration of ABO-102.
  • The Company is hopeful of having an evaluable data set in 2022.
  • Recently, new data from gene therapy showed that brain volume in three young patients increased at 24 months.
  • Price Action: ABEO shares are up 1.60% at $1.27 during the market session on the last check Wednesday.
  • Related content: Benzinga's Full FDA Calendar.
Market News and Data brought to you by Benzinga APIs
Posted In: BiotechNewsPenny StocksHealth CareFDAGeneralBriefsgene therapy
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!